Abstract |
Despite the poor survival of patients with advanced (stage IIIB with pleural effusion or stage IV) non-small-cell lung cancer, the introduction of new chemotherapeutic agents has improved survival and quality of life with reduced toxicity compared with older cisplatin-based therapies. Randomized trials support the use of two- drug combinations for patients of all ages with performance status of 0 to 1. These two- drug combinations should contain at least one new agent. Some of these two- drug combinations may be acceptable in selected patients with a performance status of 2. Newer, targeted therapies hold promise to improve outcome without adding a great deal of additional toxicity.
|
Authors | Paul A Bunn Jr |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 20
Issue 18 Suppl
Pg. 23S-33S
(Sep 15 2002)
ISSN: 0732-183X [Print] United States |
PMID | 12235221
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
|
Chemical References |
- Deoxycytidine
- Vinblastine
- Irinotecan
- Cisplatin
- Vinorelbine
- Camptothecin
- Gemcitabine
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Cisplatin
(administration & dosage)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Humans
- Irinotecan
- Lung Neoplasms
(drug therapy, pathology)
- Neoplasm Staging
- Palliative Care
- Randomized Controlled Trials as Topic
- Vinblastine
(administration & dosage, analogs & derivatives)
- Vinorelbine
- Gemcitabine
|